Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

On May 5, 2020 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that the Company will release its first quarter 2020 financial results on Tuesday, May 12, 2020, after the close of US markets (Press release, Curis, MAY 5, 2020, View Source [SID1234557040]). Management will host a conference call on the same day at 4:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the ‘Investors’ section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

Scholar Rock Announces Initiation of Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy

On May 5, 2020 Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported the initiation of patient dosing in the DRAGON Phase 1 dose escalation and dose expansion clinical trial of SRK-181 in patients with locally advanced or metastatic solid tumors (Press release, Scholar Rock, MAY 5, 2020, businesswire.com/news/home/20200505005992/en/Scholar-Rock-Announces-Initiation-Patient-Dosing-Phase [SID1234557056]). SRK-181 is a potent and highly selective inhibitor of latent TGFβ1 activation and is being developed to increase responses to immunotherapy by overcoming primary resistance to anti-PD-1 or anti-PD-L1 antibody therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Based on emerging evidence in the field from human and preclinical data implicating TGFβ1 as a key culprit in primary resistance to anti-PD-(L)1 therapy, we are excited to be investigating a rational approach to combination immunotherapy," said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. "Our team’s focus and determination to advance SRK-181 and this Phase 1 trial, particularly as the evolving COVID-19 pandemic has resulted in various challenges, has been truly impressive. We remain committed to our mission of developing important therapies for patients and the initiation of dosing in this proof-of-concept trial represents an important milestone for us and our TGFβ1 platform."

DRAGON Phase 1 Proof-of-Concept Trial

The DRAGON Phase 1 open-label, dose escalation and dose expansion clinical trial is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181 in adult patients with locally advanced or metastatic solid tumors enrolled across multiple sites in the U.S. The two-part trial consists of a dose escalation portion (Part A) for SRK-181 as both a single agent and in combination with approved anti-PD-(L)1 therapy, followed by a dose expansion portion (Part B) evaluating SRK-181 in combination with approved anti-PD-(L)1 therapy in multiple tumor-specific cohorts. Intravenous (IV) SRK-181 is administered every 3 weeks (Q3W) and additional dosing regimens may be explored.

Due to the COVID-19 pandemic and the anticipated pace of enrollment, Scholar Rock now plans to provide an update on dose escalation of SRK-181 as a single agent as well as in combination with anti-PD-(L)1 therapy in the fourth quarter of 2020. Clinical response and safety data are anticipated in 2021. Timing of data read-outs may be further impacted by COVID-19-related disruptions.

Part A Dose Escalation: Part A of the Phase 1 trial assesses SRK-181 both as a single agent and in combination with approved anti-PD-(L)1 therapy and will be conducted in a staggered fashion. The safety, PK, and activity of SRK-181 will be evaluated, including effects upon biomarkers, such as CD8 T cell infiltration, based on biopsies before and after treatment.

Part A1 evaluates SRK-181 as a single agent in patients with locally advanced or metastatic solid tumors. The dose escalation will follow a modified 3+3 design and assess doses starting at 80 mg up to 2400 mg (based on an average body weight of approximately 80 kg).

Part A2 evaluates SRK-181 in combination with anti-PD-(L)1 therapy in patients with locally advanced or metastatic solid tumors that exhibit primary resistance to anti-PD-(L)1 antibodies. Lack of response is characterized as either stable disease or progressive disease following at least three cycles of treatment with an approved anti-PD(L)1 therapy, either alone or in combination with chemotherapy. Patients must have received their most recent dose of anti-PD-(L)1 therapy within six months of enrollment. In combination with SRK-181, patients will be treated with the same anti-PD-(L)1 therapy that they had previously tried and did not experience a response. The dose escalation will follow a 3+3 design and assess doses up to 2400 mg.

Part B Dose Expansion: Part B of the trial consists of multiple parallel cohorts to evaluate the anti-tumor activity of SRK-181 in combination with anti-PD-(L)1 therapy. The target indications are expected to include non-small cell lung cancer, urothelial carcinoma, and cutaneous melanoma, amongst other solid tumor types.

Each cohort will enroll up to 40 patients with locally advanced or metastatic solid tumors for which anti-PD-(L)1 therapy is approved and have demonstrated primary resistance, characterized as a lack of response (stable or progressive disease) following at least three cycles of treatment. Patients must have received their most recent dose of anti-PD-(L)1 therapy within six months of enrollment. Similar to Part A2, patients will be treated with SRK-181 in combination with the same anti-PD-(L)1 therapy that they had previously tried and did not experience a response.

About SRK-181

SRK-181 is a potent and highly selective inhibitor of TGFβ1 activation and is an investigational product candidate being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 antibodies. TGFβ1 is the predominant TGFβ isoform expressed in many human tumors, particularly for those tumors where checkpoint therapies are currently approved. Based on analyses of human tumors that are resistant to anti-PD-(L)1 therapy, data suggests TGFβ1 is a key contributor to excluding immune cell entry into the tumor microenvironment, thereby preventing normal immune function. By overcoming this immune cell exclusion, Scholar Rock believes SRK-181 has the potential to induce tumor regression when administered in combination with anti-PD-(L)1 therapy. A Phase 1 proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors is ongoing. The effectiveness and safety of SRK-181 have not been established and SRK-181 has not been approved for any use by the FDA or any other regulatory agency.

Bio-Techne To Present At The BofA Securities 2020 Health Care Conference

On May 5, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual BofA Securities 2020 Health Care Conference on Wednesday, May 13, 2020 at 9:40 a.m. EDT (Press release, Bio-Techne, MAY 5, 2020, View Sourcenews/detail/188/bio-techne-to-present-at-the-bofa-securities-2020-health-care-conference" target="_blank" title="View Sourcenews/detail/188/bio-techne-to-present-at-the-bofa-securities-2020-health-care-conference" rel="nofollow">View Source [SID1234556997]). A live webcast of the presentation can be accessed via Bio-Techne’s Investor Relations website at View Source or through the following link http://www.veracast.com/webcasts/bofa/healthcare2020/id62109638.cfm.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Cerus Corporation Announces First Quarter 2020 Results

On May 5, 2020 Cerus Corporation (Nasdaq: CERS) reported financial results for the first quarter ended March 31, 2020 (Press release, Cerus, MAY 5, 2020, View Source [SID1234557021]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent developments and highlights include:

Total first quarter 2020 revenue of $24.6 million
Quarterly product revenue of $18.6 million, a 6% increase compared to the prior year quarter
Global demand for INTERCEPT kits grew during the first quarter with the calculated number of treatable platelet doses up 14% compared to the same period in 2019
Government contract revenue of $6.0 million
Reaffirming 2020 full year product revenue guidance range of $89 million to $93 million representing an approximately 20% to 25% increase over 2019 reported product revenue.
Strengthened balance sheet with a $63.3 million public offering of common stock. At March 31, 2020, the Company had cash, cash equivalents and short-term investments of $133.1 million.
Announced strategic organizational changes to align teams around key commercial growth and product portfolio pipeline development targets.
Formed a collaborative research group with the aim of optimizing the characteristics and dosing of convalescent plasma as a potential therapy for COVID-19 patients.
Further strengthened the Company’s collaboration with the Biomedical Advanced Research and Development Authority (BARDA) with an incremental $14 million available under the contract.
"First quarter product revenue of $18.6 million exceeded our internal expectations despite the tumultuous macro environment created by the global COVID-19 pandemic. The emergence of SARS-CoV-2 has highlighted the need for comprehensive preparedness planning for healthcare systems and the corresponding obligation to safeguard the blood supply chain. The INTERCEPT Blood System has played a critical role for many blood centers by reducing the risk of transfusion transmitted infections," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. "In the face of this crisis, I am proud of the actions taken by the Cerus employees designed to make sure that the blood centers and hospitals have access to INTERCEPT Blood System, even in the regions hardest hit by the pandemic."

"It is unclear as to the extent and duration that the COVID-19 impact will have on the global transfusion medicine industry and on healthcare in general, but given the critical need for blood and blood components, we are cautiously optimistic about the health of our business and our ability to further our mission to make INTERCEPT the standard of care," continued Greenman.

Revenue

Product revenue during the first quarter of 2020 was $18.6 million, compared to $17.5 million during the same period in 2019. Revenue growth during the quarter benefited from increased demand for INTERCEPT platelet kit sales in the U.S., offset partially by the year-over-year product mix shift in France and a decrease in kit sales in the Middle East due to the timing of distributor orders.

Government contract revenue from the Company’s BARDA agreement was $6.0 million during the first quarter of 2020, compared to $4.5 million during the same period in 2019, as a result of increasing INTERCEPT red blood cell development activities. With the recently announced amendment, the total potential value of the current BARDA agreement is now $214 million with $50 million recognized as revenue to date.

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. The development of the INTERCEPT red blood cell program has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600009C.

Gross Margins

Gross margins on product revenue during the first quarter of 2020 were 55%, compared to 52% for the first quarter of 2019. Gross margins during the quarter benefited from continued economies of scale and resulting lower per unit costs, driven by increased manufacturing production to meet existing and expected future growth in demand for INTERCEPT.

Operating Expenses

Total operating expenses for the first quarter 2020 were $31.7 million compared to $29.6 million for the same period the prior year.

Selling, general, and administrative (SG&A) expenses for the first quarter of 2020 totaled $15.9 million, compared to $16.2 million for the first quarter of 2019. The year-over-year decline was primarily due to lower marketing and travel related expenses, both driven in part by the COVID-19 pandemic.

Research and development (R&D) expenses for the first quarter of 2020 were $15.8 million, compared to $13.4 million for the first quarter of 2019. The increase in year-over-year R&D expenses were primarily due to increased costs associated with initiatives for expanded INTERCEPT platelet label claims and costs for our red blood cell program, namely activities under our BARDA agreement.

Net Loss

Net loss for the first quarter of 2020 was $16.5 million, or $0.10 per diluted share, compared to a net loss of $18.8 million, or $0.14 per diluted share, for the first quarter of 2019.

Cash, Cash Equivalents and Investments

At March 31, 2020, the Company had cash, cash equivalents and short-term investments of $133.1 million, compared to $85.7 million at December 31, 2019.

At March 31, 2020, the Company had approximately $39.5 million in outstanding term loan debt compared to $39.4 million at December 31, 2019.

2020 Product Revenue Guidance

The Company expects 2020 product revenue to be in the range of $89 million to $93 million, unchanged from the prior guidance originally provided on January 13, 2020. The guidance range represents approximately 20% to 25% growth compared to 2019 reported product revenue.

QUARTERLY CONFERENCE CALL

The Company will host a conference call and webcast at 4:30 P.M. EDT this afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To access the live webcast, please visit the Investor Relations page of the Cerus website at View Source Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on the Company’s website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 8484403. The replay will be available approximately three hours after the call through May 19, 2020.

DelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

On May 5, 2020 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported it has enrolled 22 patients in the adjuvant arm of the Company’s ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide — or TMZ — maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) with VAL-083 (Press release, DelMar Pharmaceuticals, MAY 5, 2020, View Source [SID1234557041]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The adjuvant arm of the Phase 2 study of VAL-083 being conducted at the MD Anderson Cancer Center (MDACC) is designed to enroll up to 24 newly-diagnosed patients who have undergone surgery and chemoradiation with TMZ but will now receive VAL-083 in place of standard of care TMZ for adjuvant therapy. Additionally, in the recurrent arm of the study, which is also being conducted at MDACC, 72 patients out of a planned 83 patients have now been enrolled. DelMar continues to actively enroll patients in both trial arms of the clinical study, even in light of the COVID-19 pandemic.

DelMar previously announced that it had completed full enrollment of the planned 29 patients in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed, MGMT-unmethylated GBM. The trial is being conducted at the Sun Yat-sen University Cancer Center in Guangzhou, China, and is designed to determine whether first-line therapy with VAL-083 treatment improves progression free survival. The current standard of care is first line TMZ with radiation.

Pending meeting formats and other unforeseen changes, DelMar currently intends to announce additional clinical trial updates concomitant with planned scientific poster presentations at or around the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program May 29-31, 2020, and at or around the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II June 22-24, 2020.

About VAL-083

VAL-083 (dianhydrogalactitol) is a "first-in-class", bifunctional DNA-targeting agent that introduces inter-strand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute (NCI). DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by common mechanisms of chemoresistance, including MGMT, in cancer cell models and animal studies. Further details regarding these studies can be found at:

View Source